BOLOGNA, Italy and HUNTINGDON VALLEY, Pa. and GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that it has entered into a strategic co-promotion partnership with Menarini Silicon Biosystems (MSB), the pioneer of liquid biopsy and rare cell technologies, for its CELLSEARCH Circulating Endothelial Cell (CEC) Kit*, relevant to study progression of COVID-19 disease, and other COVID-19-related products.
Effective immediately, Menarini’s CELLSEARCH system, CELLSEARCH CEC kit and COVID-19 related products will be marketed and sold by OpGen to infectious disease healthcare providers and researchers in North America through its dedicated team of sales and marketing experts.The partnership will focus on promoting Menarini’s CELLSEARCH system for CEC application, for the enrichment and enumeration of CEC from whole blood. CEC count is useful in studying the progression of COVID-19 and potentially in identifying patients at risk of developing more severe complications.“We are excited to partner with OpGen for the commercialization of our CELLSEARCH CEC Kit and our expanding portfolio of COVID-19 related products in the U.S. market,” said Fabio Piazzalunga, President and CEO of Menarini Silicon Biosystems, Inc. “This deal further extends the strategic distribution partnership which Menarini has built over the past 15 months in eleven European markets for OpGen’s subsidiary Curetis GmbH’s Unyvero platform and forms another element of our strategic presence in the infectious disease diagnostics market.”“This commercial partnership further adds to the available portfolio of infectious disease tests that our OpGen sales and marketing team can bring to our network of customers in the U.S.,” stated Oliver Schacht, CEO of OpGen. “With Menarini already being our exclusive strategic distribution partner in Europe since early 2019, we see this as a natural extension and expansion of our partnership at a global level.”“While MSB has traditionally focused on oncology molecular diagnostics we also have built a dedicated team of commercial experts in the U.S. in the infectious disease diagnostics market. Our team is excited to add several key products into their offering to bring a more complete solution to the COVID-19 pandemic situation,” Mr. Schacht added.About Menarini Silicon Biosystems
Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinical researchers with access to unparalleled resolution in the study of cells and their molecular characterization. The company’s CELLSEARCH and DEPArray technologies together provide an end-to-end solution** for enumeration and sorting of rare cells with single-cell precision.Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley, Pa., U.S., is a wholly owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company headquartered in Florence, Italy, with 17,640 employees in 136 countries.About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with its subsidiaries, Curetis GmbH and Ares Genetics GmbH, OpGen is developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.
For more information, please visit www.opgen.com.OpGen Forward-Looking Statement
This press release includes statements regarding the Menarini Silicon Biosystems commercial partnership for COVID-19 related tests by OpGen. These statements and other statements regarding the Companies’ future plans and goals constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen’s business, please review the Company’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.* The Circulating Endothelial Cell Kit (CEC) is for Research Use Only. Not for use in diagnostic procedures. The performance characteristics, safety, and effectiveness have not been established and are not cleared or approved by the FDA.
    
**The workflow described is for research use only. Not for use in diagnostic procedures. The performance characteristics, safety, and effectiveness of the workflow have not been established and are not cleared or approved by the FDA.Menarini Silicon Biosystems
Liz Dowling, (415) 388-2794
Dowling & Dennis PR
[email protected]OpGen Press Contact
Matthew Bretzius 
FischTank PR
[email protected]OpGen Investor Contact
Joe Green
Edison Group
[email protected] 

Bay Street News